Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized study of PF-08634404 plus chemotherapy vs pembrolizumab plus chemotherapy in advanced non-small cell lung cancer
jRCT2031250536Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing PF-08634404 + chemotherapy with pembrolizumab + chemotherapy (2 arms). Primary endpoints: Overall Survival and Progression-free survival (BICR). Started Jan 2026; status: recruiting.
02
Drugs
PF-08634404pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250536.